VYGR Form 4 reports sale transactions

Sandrock Alfred reported open-market sale transactions in a Form 4 filing for VYGR.

Rhea-AI Filing Summary

Sandrock Alfred reported open-market sale transactions in a Form 4 filing for VYGR. The filing lists transactions totaling 12,192 shares at a weighted average price of $3.78 per share. Following the reported transactions, holdings were 509,989 shares.

Insider Trade Summary

Net Seller: 12,192 shares

Net Sell 1 txn

Insider Sandrock Alfred

Role President and CEO

Sold 12,192 shs ($46K)

Type	Security	Shares	Price	Value
Sale	Common Stock	12,192	$3.78	$46K

Holdings After Transaction: Common Stock — 509,989 shares (Direct)

Footnotes (2)

1. F1. Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on February 9, 2026. The sales do not represent a discretionary trade by the reporting person.
2. F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.68 to $3.91, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Voyager Therapeutics (VYGR) CEO Alfred Sandrock report in this Form 4?

Alfred Sandrock reported an automatic tax-related stock sale. He sold 12,192 shares of Voyager Therapeutics common stock on February 10, 2026 to cover tax withholding from vested restricted stock units, and continued to hold 509,989 shares afterward.

How many Voyager Therapeutics (VYGR) shares did the CEO sell and at what price?

The CEO sold 12,192 shares at a weighted average price of $3.78. The filing explains the shares were sold in multiple transactions within a $3.68 to $3.91 range, with $3.78 per share reported as the weighted average price.

Why were Alfred Sandrock’s Voyager Therapeutics (VYGR) shares sold?

The shares were sold to satisfy tax withholding obligations. The Form 4 states the sale followed a durable automatic sales instruction letter, executing a sell-to-cover election related to restricted stock units that vested on February 9, 2026.

Was the Voyager Therapeutics (VYGR) CEO’s stock sale a discretionary trade?

No, the sale was not a discretionary trade by the CEO. The filing specifies that the transactions were executed under an automatic sales instruction for tax withholding, meaning they followed preset instructions rather than an active trading decision.

How many Voyager Therapeutics (VYGR) shares does the CEO own after the transaction?

Alfred Sandrock beneficially owns 509,989 shares after the sale. Following the 12,192-share sell-to-cover transaction, the Form 4 reports that his remaining ownership of Voyager Therapeutics common stock is 509,989 shares held directly.

What does the price range in the Voyager Therapeutics (VYGR) Form 4 footnote mean?

The shares were sold in multiple trades within a price range. The filing notes transactions occurred between $3.68 and $3.91 per share, with $3.78 reported as the weighted average. Detailed per-trade pricing is available upon request from the company or regulators.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/11/2026 - 04:30 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sandrock Alfred

(Last) (First) (Middle)

C/O VOYAGER THERAPEUTICS, INC.

75 HAYDEN AVENUE

(Street)

LEXINGTON MA 02421

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Voyager Therapeutics, Inc. [ VYGR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
02/10/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/10/2026		S(1)		12,192(1)	D	$3.78(2)	509,989	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on February 9, 2026. The sales do not represent a discretionary trade by the reporting person.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.68 to $3.91, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

	/s/ Gregory Shiferman, as Attorney-in-Fact for Alfred Sandrock	02/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.